Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

NCT03241940 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
CD19 Positive
Minimal Residual Disease
Philadelphia Chromosome Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy
DRUG: Cyclophosphamide
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
OTHER: Questionnaire Administration

Sponsor

Stanford University